An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
- 19 Jun 2017 Planned End Date changed from 1 Jun 2017 to 30 Nov 2017.
- 19 Jun 2017 Planned primary completion date changed from 1 Jan 2017 to 30 Nov 2017.
- 10 Jun 2017 Biomarkers information updated